Compare Quest Diagnostics Inc (DGX) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Consolidated Edison, Inc. — how do they compare? Quest Diagnostics Inc trades at $204.65 (market cap $22.80B), while Consolidated Edison, Inc. trades at $111.41 (market cap $41.26B). The key difference: Consolidated Edison, Inc. is the larger of the two by market cap, and Consolidated Edison, Inc. pays the higher dividend (3.1%). Which is the better fit depends on your goals.
| DGX | ED | |
|---|---|---|
Market Cap | $22.80B | $41.26B |
Sector | Health | Utilities |
52-Week High | $216.02 | $115.46 |
52-Week Low | $166.42 | $95.37 |
Enterprise Value | $28.82B | $68.29B |
Dividend Yield | 1.67% | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Consolidated Edison (ED) trades at $111.82, up 0.63% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings but maintains stable profitability with a 12.52% net margin. Recent news highlights grid upgrades to meet rising data center demand and the launch of New York's largest electric school bus fleet, supporting long-term growth initiatives.
ED offers a defensive utility profile with a 3.3% dividend yield and 52-year dividend growth streak. However, analyst consensus is cautious with 67% hold ratings and a $103.50 price target below current levels. Key risks include capital expenditure pressures from grid modernization and interest rate sensitivity due to high debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
